SOL-GEL TECHN. IS-10 - Asset Resilience Ratio
SOL-GEL TECHN. IS-10 (4SG) has an Asset Resilience Ratio of 43.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of SOL-GEL TECHN. IS-10 for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how SOL-GEL TECHN. IS-10's Asset Resilience Ratio has changed over time. See SOL-GEL TECHN. IS-10 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SOL-GEL TECHN. IS-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SOL-GEL TECHN. IS-10 (4SG) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €12.97 Million | 43.34% |
| Total Liquid Assets | €12.97 Million | 43.34% |
Asset Resilience Insights
- Very High Liquidity: SOL-GEL TECHN. IS-10 maintains exceptional liquid asset reserves at 43.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SOL-GEL TECHN. IS-10 Industry Peers by Asset Resilience Ratio
Compare SOL-GEL TECHN. IS-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for SOL-GEL TECHN. IS-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.34% | €12.97 Million ≈ $15.16 Million |
€29.92 Million ≈ $34.98 Million |
+30.96pp |
| 2024-12-31 | 12.38% | €4.44 Million ≈ $5.19 Million |
€35.85 Million ≈ $41.91 Million |
-54.93pp |
| 2023-12-31 | 67.31% | €30.48 Million ≈ $35.64 Million |
€45.29 Million ≈ $52.95 Million |
+21.89pp |
| 2022-12-31 | 45.42% | €21.18 Million ≈ $24.76 Million |
€46.63 Million ≈ $54.51 Million |
+11.95pp |
| 2021-12-31 | 33.47% | €23.16 Million ≈ $27.07 Million |
€69.19 Million ≈ $80.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more